Evaluation of growth hormone release and human growth hormone treatment in children with cranial irradiation-associated short stature

Abstract Human growth hormone release is affected by a variety of pharmacological and physiological stimuli. We have studied the effect of oral clonidine, insulin hypoglycemia, and exercise on plasma hGH and GHRH levels in 31 healthy short-stature children. Thirteen underwent an oral clonidine test (0.15 mg/m2), 12 an iv. insulin test (0.1 U/kg), and 6 performed exercise (running for 10 min in a defined route). GHRH-1-44 was extracted from plasma on silica columns and determined by RIA. Although all three stimuli induced a marked increase in plasma hGH levels, only clonidine induced a significant increase in plasma GHRH levels. Maximal increment in GHRH during clonidine was 6.82 ± 1.05 pmol/l (mean ± SEM) as compared with 0.51 ± 0.28 and 0.53 ± 0.62 during hypoglycemia and exercise (p<0.0005 and p<0.005), respectively. An additional 24 subjects received TRH 0.2 mg/kg iv: 8 TRH alone, 8 TRH and insulin, and 8 TRH and clonidine. Only insulin potentiated the TRH-induced TSH response with a peak of 22.0 ± 3.2 vs 16.0 ± 0.8 and 15.3 ± 1.5 mU/l (p<0.025) for TRH alone and TRH and clonidine, respectively. It is suggested that clonidine stimulates hGH secretion mainly through an enhancement of GHRH release, whereas stress stimuli such as hypoglycemia and exercise achieve hGH release by a different mechanism, possibly inhibition of somatostatin.

Download Full-text

Growth Response to Human Growth Hormone Treatment in Children with Partial and Total Growth Hormone Deficiency

Acta Paediatrica ◽

10.1111/j.1651-2227.1986.tb10288.x ◽

1986 ◽

Vol 75 (5) ◽

pp. 767-773 ◽

Cited By ~ 21

Author(s):

J. M. WIT ◽

J. A. J. FABER ◽

J. L. VAN DEN BRANDE

Keyword(s):

Growth Hormone ◽

Growth Hormone Deficiency ◽

Human Growth Hormone ◽

Growth Response ◽

Growth Hormone Treatment ◽

Human Growth ◽

Hormone Treatment ◽

Hormone Deficiency ◽

Total Growth

Download Full-text

CT-Determined Body Composition Changes with Recombinant Human Growth Hormone Treatment to Adults with Growth Hormone Deficiency

Human Body Composition ◽

10.1007/978-1-4899-1268-8_53 ◽

1993 ◽

pp. 229-231 ◽

Cited By ~ 1

Author(s):

Lars Lönn ◽

Henry Kvist ◽

Ulla Grangård ◽

Bengt-Åke Bengtsson ◽

Lars Sjöström

Keyword(s):

Growth Hormone ◽

Body Composition ◽

Growth Hormone Deficiency ◽

Human Growth Hormone ◽

Growth Hormone Treatment ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Hormone Treatment ◽

Hormone Deficiency ◽

Composition Changes

Download Full-text

Recombinant human growth hormone treatment in children with thalassemia major

Pediatrics International ◽

10.1046/j.1442-200x.1999.01139.x ◽

1999 ◽

Vol 41 (6) ◽

pp. 655-661 ◽

Cited By ~ 10

Author(s):

AYTEN Arcasoy ◽

GÖNÜL Öcal ◽

SABRI Kemahli ◽

MERIH Berberoİlu ◽

YILDIZ Yildirmak ◽

...

Keyword(s):

Growth Hormone ◽

Human Growth Hormone ◽

Growth Hormone Treatment ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Hormone Treatment ◽

Thalassemia Major

Download Full-text

Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity

BioMed Research International ◽

10.1155/2020/2308124 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Jing Wu ◽

Fei Zhao ◽

Yuan Zhang ◽

Jiang Xue ◽

Jiangying Kuang ◽

...

Keyword(s):

Growth Hormone ◽

Hormone Therapy ◽

Human Growth Hormone ◽

Growth Hormone Treatment ◽

Growth Hormone Therapy ◽

Recombinant Human Growth Hormone ◽

Human Growth ◽

Hormone Treatment ◽

Risk Markers ◽

One Year

It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.

Download Full-text